Traumatic brain injury (TBI), principally as a result of impaction on the intact closed skull, occurs in vehicular incidents, falls, acts of violence, and sports accidents. TBI is the leading cause of death and disability in the United States, with an annual incidence rate of 1.5 million. Of these, 50,000 die acutely, over 230,000 are hospitalized, and 80,000 experience long term disability. TBI affects people of all ages with most survivors suffering chronic, life-long disabilities with varying degrees of dependence. Currently, there are no therapies to treat TBI that have been demonstrated to improve functional outcomes like memory performance, which if the patient survives, is the most important clinical characteristic of a successful therapy. The lack of therapeutic intervention for a public health issue of this magnitude constitutes a healthcare crisis. We have recently demonstrated that the addition of exogenous apolipoprotein-E, or peptides derived from apoE's receptor binding domain, can significantly reduce inflammatory responses in the brain and in the periphery. Mice given TBI and then treated with COG133 at 30 minutes following head injury exhibited faster recovery times and their performance on behavioral tests recovered to pre-injury levels, whereas the behavior of head-injured saline treated mice never returned to preinjury levels of performance. In Phase 1 we systematically modified the apoE 130-150 peptide compound and successfully defined the minimal and essential residues that retain binding and anti-inflammatory activities. These data support a model where COG 133 assumes the structure of an amphipathic alpha helix that appears to be required for anti-inflammatory activity. Going beyond Phase 1, we have created COG 1410, a significantly modified and improved compound as disclosed herein. In Phase 2, we propose to test the hypothesis that the 3- dimensional structure and resistance to specific proteolytic degradation will further enhance activity in TBI, blood brain barrier penetration and therapeutic window of selected derivatives of COG1410. These studies are necessary to acquire the pre-clinical pharmacology needed to declare a clinical lead for Phase 2B studies of pre-clinical toxicology to support an IND application and Phase 3 human clinical trial studies to support an NDA application with the FDA.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-E (11))
Program Officer
Buckholtz, Neil
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Cognosci, Inc.
Research Triangle Park
United States
Zip Code
Ghosal, Kaushik; Stathopoulos, Andrea; Thomas, Dustin et al. (2013) The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features. Neurodegener Dis 12:51-8
Christensen, Dale J; Ohkubo, Nobutaka; Oddo, Jessica et al. (2011) Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 186:2535-42
Shvartsman, A L; Sarantseva, S V; Vitek, M P (2011) [Potential role of presenilin 1 in regulation of synaptic function]. Tsitologiia 53:959-67
Li, Feng-Qiao; Fowler, Kenneth A; Neil, Jessica E et al. (2010) An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. J Pharmacol Exp Ther 334:106-15
Kaufman, Nicholas A; Beare, Jason E; Tan, Arlene A et al. (2010) COG1410, an apolipoprotein E-based peptide, improves cognitive performance and reduces cortical loss following moderate fluid percussion injury in the rat. Behav Brain Res 214:395-401
Sarantseva, S V; Bol'shakova, O I; Timoshenko, S I et al. (2009) [Protein transduction domain peptide mediates delivery to the brain via the blood-brain barrier in Drosophila]. Biomed Khim 55:41-9
Hoane, Michael R; Kaufman, Nicholas; Vitek, Michael P et al. (2009) COG1410 improves cognitive performance and reduces cortical neuronal loss in the traumatically injured brain. J Neurotrauma 26:121-9
James, Michael L; Sullivan, Patrick M; Lascola, Christopher D et al. (2009) Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. Stroke 40:632-9
Tukhovskaya, Elena A; Yukin, Alexey Yu; Khokhlova, Oksana N et al. (2009) COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological recovery in a rat model of focal brain ischemia. J Neurosci Res 87:677-82
Shvartsman, A L; Sarantseva, S V; Solov'ev, K V et al. (2008) [Degeneration of growth cones in a culture of embryonic neurons of mouse with presenilin 1 gene knockout] Biofizika 53:1008-13

Showing the most recent 10 out of 11 publications